TTK Healthcare receives a balance amount of Rs. 208.39 Cr from BSV Pharma
TTK Healthcare Limited received from BSV Pharma Pvt. Ltd. a sum of Rs. 593.11 crore on 9th May, 2022
TTK Healthcare Limited received from BSV Pharma Pvt. Ltd. a sum of Rs. 593.11 crore on 9th May, 2022
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Subscribe To Our Newsletter & Stay Updated